Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial Results
Date:5/10/2013

ths ended March 31, 2013 and 2012, respectively. 

General and Administrative Expenses:  General and administrative expenses for the three months ended March 31, 2013 decreased five percent to $4.3 million from $4.6 million for the corresponding period in 2012.  The decrease was primarily attributable to decreases in personnel costs.

Consolidated Net Loss:  Net loss for the three months ended March 31, 2013 was $26.0 million, or $0.05 per share, compared to a net loss of $29.9 million, or $0.06 per share, in the corresponding period in 2012.  For the three months ended March 31, 2013, net loss included non-cash, stock-based compensation expense of $2.1 million, compared to $1.7 million in the corresponding period in 2012.

Cash and Investments:  As of March 31, 2013, Lexicon had $197.2 million in cash and investments, as compared to $223.2 million as of December 31, 2012. 

Lexicon Conference CallLexicon management will hold a conference call to discuss its clinical development progress and financial results for the first quarter of 2013 at 11:00 a.m. Eastern Time on May 10, 2013. The dial-in number for the conference call is 888-645-5785 (within the US/Canada) or 970-300-1531 (international). The conference ID for all callers is 64449185. Investors can access a live webcast of the call at www.lexpharma.com. An archived version of the webcast will be available on the website through June 10, 2013.

About LexiconLexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has multiple drug programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
2. Lexicon to Report First Quarter Financial Results on May 10, 2013
3. Lexicon To Present At The Needham Healthcare Conference
4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
5. Lexicon To Present At The BIO CEO & Investor Conference
6. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
7. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
8. Lexicon to Provide Third Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
10. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
11. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Mass. , Sept. 17, 2014 /PRNewswire/ ... disease/ulcerative colitis (CD/UC) patients eligible for biologic ... receive a biologic. Surveyed gastroenterologists cite patients, ... reason for low penetration rates, followed by ... and UC patients receiving biologics, Janssen Biotech,s ...
(Date:9/17/2014)... MARINA DEL REY, Calif. , Sept. 17, ... launch of the Prostate Vanguard, an awareness campaign to ... replace multiple rectal needle biopsies of the prostate. ... of the prostate gland through the rectum. Multi-parametric MRI ... for diagnosing clinically-significant prostate cancer (CSPC). Men need ...
(Date:9/17/2014)... 2014 Bronstein, Gewirtz & Grossman, LLC is ... securities of PDL BioPharma, Inc. ("PDL BioPharma" or the ... are advised to contact Peretz Bronstein or ... info@bgandg.com or 212-697-6484. The investigation ... executives violated federal securities laws. On September ...
Breaking Medicine Technology:The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2
... part of the eighth annual DVT (deep-vein thrombosis) Awareness Month, ... of DVT and its risk factors among patients with co-morbid ... respiratory and obesity patients.   DVT remains the ... deaths may be due to PE (pulmonary embolism).(1)  This is ...
... Ill., March 9, 2011 Hospira, Inc. (NYSE: ... announced U.S. Food and Drug Administration (FDA) approval of docetaxel. ... Hospira expects to launch the product later this month. ... variety of cancers. In 2010, U.S. sales of Taxotere were ...
Cached Medicine Technology:Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 2Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 3Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 4Hospira Announces U.S. Approval of Generic Docetaxel 2
(Date:9/17/2014)... Kathleen Doheny HealthDay Reporter ... major food and beverage companies have made good on their ... report finds. The companies, acting together through the Healthy ... the market between 2007 and 2012 and 1.5 trillion by ... "The 16 companies collectively met their pledge and exceeded their ...
(Date:9/17/2014)... at Moffitt Cancer Center, including Center Director Thomas A. Sellers, ... discovered 23 new regions of the genome that influence the ... Sept. 14 in Nature Genetics . , Prostate cancer ... 1 in 6 men will be diagnosed with the disease ... A man with one close relative, a brother or father ...
(Date:9/17/2014)... facial paralysis are perceived as being less happy simply ... facial expression, a new study from an Oregon State ... the important role the face plays in everyday communication ... with facial paralysis because of their disability, said Kathleen ... of Liberal Arts at Oregon State University. , "People ...
(Date:9/17/2014)... 2014 Tools4ever, the market ... solutions and Boston Software Systems, leader in ... relationship. Under the agreement, Tools4ever will ... functionality within its identity and password management ... healthcare automation platforms that streamline complex processes ...
(Date:9/17/2014)... Kessler Foundation is the recipient of one of ... Multiple Sclerosis (MS) Alliance. Nancy Chiaravalloti, PhD, ... Research, is principal investigator of the study, which ... in individuals with progressive multiple sclerosis. The Foundation ... the Alliance to investigators in nine countries, with ...
Breaking Medicine News(10 mins):Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 3Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 2Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 2Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 4Health News:Kessler Foundation receives first-round grant from International Progressive Multiple Sclerosis Alliance 2
... Older workers benefit most from a modest health behavior ... personal coaching. University of Illinois at Chicago researchers ... interventions assessing older workers, health behaviors and outcomes. The ... an upcoming issue of the American Journal of Public ...
... April 14 (HealthDay News) -- Trying to make the best of ... cope with losing their jobs, a new United Kingdom study finds. ... with their job loss were able to see the event as ... volunteering and study. They also took a contemplative view of ...
... SEATTLE Everyone knows that eating a low-fat, low-calorie diet ... study led by researchers at Fred Hutchinson Cancer Research Center ... body fat, diet and exercise are most effective when done ... of this randomized trial, led by Anne McTiernan, M.D., Ph.D., ...
... 14, 2011 An enzyme essential for DNA replication and ... exploited as anti-cancer therapy, say researchers at The Scripps Research ... in the April 15, 2011 issue of the journal Cell, ... flap endonucleases, which are essential to the life of a ...
... of Alberta shows that for best results in stable patients ... is the key to the best outcomes. Study co-authors Mark ... Clark, researcher in the Faculty of Nursing, along with fellow ... Public Health, and Ian Paterson in the Faculty of Medicine ...
... During the winter of 2008�, a three-week armed conflict ... named "Operation Cast Lead" resulted in hundreds of rocket ... this time children and their families spent hours and ... Although the psychological effects of children,s health are ...
Cached Medicine News:Health News:Older workers benefit from high-tech, high-touch health promotion 2Health News:Good Attitude Critical When Coping With Layoff Trauma 2Health News:Study finds diet plus exercise is more effective for weight loss than either method alone 2Health News:Study finds diet plus exercise is more effective for weight loss than either method alone 3Health News:Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target 2Health News:Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target 3Health News:Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target 4Health News:Heart needs work after heart attack: U of A Study challenges the notion that the heart must rest 2Health News:Teachers-based intervention provides stress resistance in war-exposed children 2
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
... The Guidant Flextend lead ... pace/sense lead with an ... extendable/retractable helix design offers ... for permanent implantation in ...
... The PY series leads are ... leads for stimulation of either the ... active fixation screw can be extended ... pin. The lead tip contains an ...
Used with permanent pacing leads....
Medicine Products: